All PlansCoverageHigh impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology, Pulmonology·Medical Policy
Effective date
Mar 16, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated coverage criteria for six specialty drugs including Lurbinectedin (Zepzelca) for lung cancer, Ziv-aflibercept (Zaltrap) for colon/rectal cancer, Atezolizumab (Tecentriq) for various cancers, and three other oncology medications. Changes include new FDA-approved indications, updated combination therapy requirements, and modified continuation criteria.
Action Required
By March 16, 2026: Prior authorization team must update approval criteria for Lurbinectedin (Zepzelca), Ziv-aflibercept (Zaltrap), Atezolizumab (Tecentriq), Elivaldogene autotemcel (Skysona), and Tafasitamab-cxix (Monjuvi). Review full policy documents at provided URLs to update internal approval workflows and documentation requirements. Notify oncology providers of new combination therapy requirements and continuation criteria changes. Claims may be denied if new criteria are not met.